Siemens launches PEV software for CT colongraphy, introduces future CT applications

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Siemens Medical Solutions this week introduced syngo Colonography with PEV (polyp enhanced viewing) software, an FDA approved advanced application for CT colonography, as well as future CT software applications including Advanced Bone Removal for syngo InSpace4D, syngo body perfusion CT, and CT Respiratory Gating for radiation therapy planning.

PEV is an optional add-on to Siemens syngo Colonography software. It is designed as a second-reader tool for automated identification of lesions in the colon and allows the radiologist to make a computer-assisted 'second pass' over the patient data, Siemens said.

PEV can be activated as the radiologist begins the primary read. The PEV results are ready for reviewing as the radiologist confirms the end of the primary read. The PEV tool then highlights potential lesions that were not marked by the radiologist, in addition to all potential lesions marked by the radiologist during the first read, and also indicates potential lesions marked by the radiologist that were not visualized by the PEV tool.

In future CT software applications, Siemens' Advanced Bone Removal technology will be a feature of syngo InSpace4D designed to improve pre-operative planning for surgical procedures. The automated workflow tool facilitates fast segmentation and removal of bony structures. It provides enhanced visualization of vascular structures, stenoses, aneurysms and stents, plus complex fractures. Advanced Bone Removal is currently under 510(k) review and is not yet commercially available in the United States.

syngo Body Perfusion CT enables the functional diagnosis of organs and tumors, interventional therapy planning and therapy monitoring. It is a works in progress and not commercially available in the U.S.

CT Respiratory Gating supplies information about tumor motions during the patient's breathing. These applications will be available in mid-2005. The application is currently under 510K review and is not yet commercially available in the U.S.